Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;71(8):702-7.
doi: 10.1097/NEN.0b013e31825f2e5d.

DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome

Kazuya Motomura  1 , Michel Mittelbronn, Werner Paulus, Benjamin Brokinkel, Kathy Keyvani, Ulrich Sure, Karsten Wrede, Yoichi Nakazato, Yuko Tanaka, Daniela Pierscianek, Young-Ho Kim, Luigi Mariani, Anne Vital, Hiroko Ohgaki
Affiliations

DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome

Kazuya Motomura et al. J Neuropathol Exp Neurol. 2012 Aug.

Abstract

Primary glioblastomas develop with a short clinical history, without evidence for less malignant precursor lesions, while secondary glioblastomas slowly develop via progression from diffuse astrocytoma (WHO grade II) or anaplastic astrocytoma (WHO grade III). The time until progression and the clinical outcome of diffuse astrocytomas vary significantly. We have shown that IDH1 mutations reliably distinguish between primary glioblastomas (without IDH1 mutations) and secondary glioblastomas (with IDH1 mutations). The most frequent genetic alteration shared by primary and secondary glioblastomas is loss of heterozygosity at 10q (up to 60% of cases). Here, we first assessed The Cancer Genome Atlas data to identify gene loss at 10q in glioblastomas with or without IDH1 mutations. Using log-ratio thresholds of -1.0, 10 genes were identified; with the log-ratio thresholds of -2.0, only the DMBT1 (deleted in malignant brain tumor 1) gene at 10q26.13 remained as a deleted gene in glioblastomas with or without IDH1 mutations (12.5% vs 8.0%). We then analyzed a total of 404 gliomas by differential polymerase chain reaction and found a DMBT1 homozygous deletion at a similar frequency in primary and secondary glioblastomas (19.6% vs 20.8%). A fraction (11.3%) of diffuse astrocytomas showed a DMBT1 homozygous deletion that was significantly associated with a shorter overall survival (52.8 vs 84.0 months; p = 0.003). These results indicate that a DMBT1 homozygous deletion is present in a fraction of diffuse astrocytomas and that it is associated with an unfavorable clinical outcome.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms